PREDILIFE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.7 EUR | -51.57% |
|
+50.98% | +35.09% |
| 2023 | Predilife: a project accredited by Finance Innovation | CF |
| 2023 | Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 289K 311K | Sales 2023 * | - | Capitalization | 28.5M 30.66M |
|---|---|---|---|---|---|
| Net income 2022 * | - | Net income 2023 * | - | EV / Sales 2022 | 79.4 x |
| Net cash position 2022 | 3.52M 3.79M | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | 20 |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 92.59% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -51.57% | ||
| 1 week | +50.98% | ||
| Current month | +49.51% | ||
| 1 month | +54.62% | ||
| 3 months | +42.59% | ||
| 6 months | +30.51% | ||
| Current year | +35.09% |
1 week
5.00
24.00
1 month
4.0824.00
Current year
3.6024.00
1 year
3.6024.00
3 years
3.6024.00
5 years
3.6024.00
10 years
3.6024.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 03-12-31 |
Émilien Gauthier
CTO | Chief Tech/Sci/R&D Officer | - | 06-12-31 |
Marion Renelier
LAW | General Counsel | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Vilgrain
BRD | Director/Board Member | 44 | 17-12-31 |
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 03-12-31 |
Antoine Bricard
BRD | Director/Board Member | 56 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 7.7 | -51.57% | 16,463 |
| 24-05-02 | 15.9 | +208.74% | 33,873 |
| 24-04-30 | 5.15 | +0.98% | 215 |
| 24-04-29 | 5.1 | 0.00% | 2,419 |
| 24-04-26 | 5.1 | +18.60% | 14,088 |
Real-time Euronext Paris, May 03, 2024 at 11:29 am EDT
More quotes
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women,over 300,000 French women and 500,000 English.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +35.09% | 30.7M | |
| -16.10% | 11.41B | |
| +67.65% | 3.81B | |
| -30.20% | 2.3B | |
| -14.31% | 2.16B | |
| -26.03% | 1.56B | |
| +36.95% | 1.19B | |
| -2.40% | 760M | |
| -38.57% | 444M | |
| +13.72% | 339M |
- Stock Market
- Equities
- ALPRE Stock
